Activity

Filter

Cancel
Date Panel Item Activity
12 actions
Genetic Epilepsy v0.1303 SMARCB1 Zornitza Stark Phenotypes for gene: SMARCB1 were changed from Coffin-Siris syndrome and epilepsy to Coffin-Siris syndrome 3, MIM# 614608; Epilepsy
Genetic Epilepsy v0.1302 SMARCB1 Zornitza Stark Classified gene: SMARCB1 as Green List (high evidence)
Genetic Epilepsy v0.1302 SMARCB1 Zornitza Stark Gene: smarcb1 has been classified as Green List (High Evidence).
Genetic Epilepsy v0.1301 SMARCB1 Zornitza Stark Marked gene: SMARCB1 as ready
Genetic Epilepsy v0.1301 SMARCB1 Zornitza Stark Gene: smarcb1 has been classified as Green List (High Evidence).
Genetic Epilepsy v0.1301 SMARCB1 Zornitza Stark Publications for gene: SMARCB1 were set to PMID:33006724
Genetic Epilepsy v0.1300 SMARCB1 Zornitza Stark Classified gene: SMARCB1 as Green List (high evidence)
Genetic Epilepsy v0.1300 SMARCB1 Zornitza Stark Gene: smarcb1 has been classified as Green List (High Evidence).
Genetic Epilepsy v0.1299 SMARCB1 Zornitza Stark reviewed gene: SMARCB1: Rating: GREEN; Mode of pathogenicity: None; Publications: 22426308, 23906836, 23929686; Phenotypes: Coffin-Siris syndrome 3, MIM# 614608; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Genetic Epilepsy v0.1299 SMARCB1 Zornitza Stark Classified gene: SMARCB1 as Red List (low evidence)
Genetic Epilepsy v0.1299 SMARCB1 Zornitza Stark Gene: smarcb1 has been classified as Red List (Low Evidence).
Genetic Epilepsy v0.1297 SMARCB1 Belinda Chong gene: SMARCB1 was added
gene: SMARCB1 was added to Genetic Epilepsy. Sources: Literature
Mode of inheritance for gene: SMARCB1 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for gene: SMARCB1 were set to PMID:33006724
Phenotypes for gene: SMARCB1 were set to Coffin-Siris syndrome and epilepsy
Review for gene: SMARCB1 was set to RED
Added comment: A single 8-year-old male with a p.Arg366Cys mutation of the SMARCB1 gene. Speech impairment and intellectual disability were reported. At the age of 6.3 years, he experienced his first generalized seizure during sleep. CBZ (16 mg/kg/day) was started and later switched to VPA (22 mg/kg/day) that could exert an additional role as a mood stabilizer, from which the hyperactive patient could benefit. Since then, he has been seizure-free. Brain MRI was normal.
Sources: Literature